Primary and secondary objectives
toxicities, DLTs
The primary objective was to determine the dose limiting toxicities (DLTs) and maximum tolerated dose (MTD) of sorafenib in combination with riluzole. Secondary objectives included characterizing the pharmacokinetic profile, and examining the correlation between clinical or radiographic response with GRM1 expression, MAPK/PI3K/AKT pathway signaling components, and expression of apoptotic protein family members including BCL-2 and BIM.